Menu
Search
|

Menu

Close
X

Achillion Pharmaceuticals Inc ACHN.OQ (NASDAQ Stock Exchange Global Select Market)

3.00 USD
-0.01 (-0.33%)
As of 2:29 AM IST
chart
Previous Close 3.01
Open 3.02
Volume 528,688
3m Avg Volume 481,616
Today’s High 3.12
Today’s Low 2.98
52 Week High 5.66
52 Week Low 2.60
Shares Outstanding (mil) 136.76
Market Capitalization (mil) 650.99
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.43 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
15
FY15
66
EPS (USD)
FY17
-0.312
FY16
-0.451
FY15
-0.108
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
43.40
5.77
Price to Book (MRQ)
vs sector
1.80
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.13
16.52
LT Debt to Equity (MRQ)
vs sector
0.06
12.22
Return on Investment (TTM)
vs sector
-17.34
14.43
Return on Equity (TTM)
vs sector
-17.36
16.13

EXECUTIVE LEADERSHIP

David Scheer
Independent Chairman of the Board, Since 2016
Salary: --
Bonus: --
Milind Deshpande
President, Chief Executive Officer, Director, Since 2013
Salary: $590,000.00
Bonus: $218,144.00
Mary Fenton
Chief Financial Officer, Executive Vice President, Since 2015
Salary: $371,000.00
Bonus: $101,932.00
Martha Manning
Executive Vice President, General Counsel, Corporate Secretary, Since 2016
Salary: --
Bonus: --
Joseph Truitt
Executive Vice President, Chief Commercial Officer, Since 2014
Salary: $371,000.00
Bonus: $112,125.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

300 George St
NEW HAVEN   CT   06511-6624

Phone: +1203.6247000

Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system. The complement system is part of the human innate immune system. Its clinical compound from its complement inhibitor platform is ACH-4471. ACH-4471 is a potent and specific inhibitor of factor D, which demonstrated complete inhibition of the complement alternative pathway in human healthy volunteers in a Phase I clinical trial. The Company has discovered and advanced multiple compounds into clinical development, including sovaprevir, odalasvir, and ACH-3422 in its hepatitis C virus (HCV) program.

SPONSORED STORIES